Table 3.

Studies reporting statistics on a relation between galactomannan evolution after diagnosis and outcome.

References	Population	N	Kinetic parameter	Measured outcome	p-value
Vehreschild et al., 2017d	Majority hematological	40	Mean sGM at day 7	0.3 in week 12 survivors vs. 1.1 in week 12 non-survivors	0.354
			Mean sGM at day 14	0.3 in week 12 survivors vs. 1.3 in week 12 non-survivors	0.559
			Mean of (day 14 sGM – day 7 sGM)	1.26 in week 12 survivors vs. 0.82 in non-survivors	0.617
Neofytos et al., 2015	SOT, hematological, solid tumor	47	Baseline sGM – Week 2 sGM	Mean difference 0.58 between week 6 responders vs. week 6 non-responders	0.03
			Baseline sGM – Week 6 sGM	Mean difference 0.65 between week 6 responders vs. week 6 non-responders	0.03
			Baseline sGM – Week 2 sGM	Mean difference 0.72 between week 12 responders vs. week 12 non-responders	0.02
			Baseline sGM – Week 6 sGM	Mean difference 0.98 between week 12 responders vs. week 12 non-responders	0.01
			sGM remaining < 0.5	OR 4.1 for week 6 response	0.07
			sGM remaining < 0.5	OR 4.5 for week 12 response	0.05
			sGM remaining < 0.5	OR 4.3 for week 6 survival	0.10
			sGM remaining < 0.5	OR 6.5 for week 12 survival	0.02
Han et al., 2015	Pediatric hematological	45	Week 1 median sGM	0.39 in week 12 survivors vs. 1.64 in week 12 non-survivors	0.015
			Week 2 median sGM	0.38 in week 12 survivors vs. 2.76 in week 12 non-survivors	0.004
			Week 1 sGM < 1.5	Predicts week 12 survival with sensitivity 61.5%, specificity 89.3%, NPV 83.3%, PPV 72.7%
Teering et al., 2014a,e	Mixed ICU	44	Maximum sGM – baseline sGM	0.11 in in-hospital survivors vs. 0.48 in non-survivors	0.017
Chai et al., 2014	Majority hematological	147	Week 1 sGM – baseline sGM	Greater decline in week 12 responders in voriconazole treated patients (effect size not reported)	0.001
			Week 2 sGM – baseline sGM	Greater decline in week 12 responders in voriconazole treated patients (effect size not reported)	0.046
			Week 4 sGM – baseline sGM	Greater decline in week 12 responders in amphotericin B treated patients (effect size not reported)	0.072
Khanna et al., 2013f	Adults and children, no pathology specified	57	Increasing sGM	5.4% of day 30 survivors vs. 64.9% of day 30 non-survivors had increasing sGM	0.02
Nouér et al., 2012	Multiple myeloma	98	sGM < 0.5 within 7 days	Adjusted OR 2.9 for favorable week 6 response	0.048
			sGM < 0.5 within 7 days	45.5% of week 6 survivors vs. 22.6% of week 6 non-survivors had sGM < 0.5 within 7 days	0.03
			sGM < 0.5 within 7 days	Adjusted OR 2.9 for week 6 survival	0.048
Hadrich et al., 2012	Hematological	58	7 × (Week 1 sGM – baseline sGM)/days between tests	HR 0.709 for mortality	NS
Bergeron et al., 2012	Hematological	57	sGM area under the curve	No association found with day 60 survival
			Rate of sGM decline	No association found with day 60 survival
Park S. H. et al., 2011	Hematological	58	sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.663 for week 6 clinical failure	<0.05
			sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.819 for week 12 clinical failure	<0.05
Park S. Y. et al., 2011	Hematological, SOT	110	sGM remaining > 0.5 for more than 3 months	HR 7.14 day 90 mortality	<0.001
Nouér et al., 2011	Hematological	115	sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.819 for week 6 clinical failure	<0.001
Koo et al., 2010	Hematological, SOT, solid tumor	93	(Baseline sGM – week 1 sGM)/days between tests	Adjusted HR 0.78 for week 6 survival	0.02
Maertens et al., 2009g	Neutropenic hematological	70	sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.588 for week 6 clinical failure	<0.05
			sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.886 for week 12 clinical failure	<0.05
			sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.752 for week 6 EORTC-MSG response failure	<0.05
Woods et al., 2007b	Hematological	56	sGM remaining > 0.5 for more than 2 weeks	Kappa coefficient 0.861 for mortality	<0.0001
Boutboul et al., 2002c	Hematological	58	Increase of week 1 sGM < 1.0 over baseline	Predicts favorable week 6 response with sensitivity 44%, specificity 87%, PPV 94%
			Increase of week 2 sGM < 1.0 over baseline	Predicts favorable week 6 response with sensitivity 55%, specificity 92%, PPV 92%
Salonen et al., 2000c,h	Hematological, SOT	18	sGM remaining > 1.0	100% of non-survivors vs. 20% of survivors had sGM remaining > 1.0	0.002

SOT, Solid organ transplantation; sGM, Serum galactomannan; OR, Odds ratio; HR, Hazard ratio; NS, Not significant; PPV, Positive predictive value. N;

^aModification of the 2008 EORTC-MSG classification criteria;

^b2002 EORTC-MSG classification criteria;

^cAuthor's own classification criteria;

^dOnly caspofungin treated patients;

^eAlso included possible cases;

^fInterval between serial sGM assessments not specified;

^gOnly pulmonary invasive aspergillosis;

^hNo interval specified between tests, or for outcome assessment.